2552.HK
Latest Trade
5.98HKDChange
0.18(+3.10%)Volume
766,500Today's Range
-
6.0852 Week Range
-
9.00As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 5.80 |
|---|---|
Open | 5.99 |
Volume | 766,500 |
3M AVG Volume | 22.76 |
Today's High | 6.08 |
Today's Low | 5.85 |
52 Week High | 9.00 |
52 Week Low | 2.47 |
Shares Out (MIL) | 949.63 |
Market Cap (MIL) | 6,287.17 |
Forward P/E | -7.33 |
Dividend (Yield %) | -- |
Hua Medicine Says Unit Enters Collaboration Agreement With Bayer Healthcare
Hua Medicine Posts HY Loss Before Tax Of About Rmb173.5 Million
Hua Medicine Says Dorzagliatin's Phase III Metformin Combination Trial Met Primary Efficacy And Safety End Point
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Industry
Biotechnology & Drugs
Contact Info
Hua Medicine, 275 Ai Di Sheng Road
SHANGHAI, SHA
201203
China
+86.21.58869997
Executive Leadership
Robert T. Nelsen
Non-Executive Chairman of the Board
Li Chen
Chief Executive Officer, Founder, Chief Scientific Officer, Executive Director
Chien Cheng Lin
Chief Financial Officer, Executive Vice President, Executive Director
Yunlong Du
Senior Vice President - Regulatory, Clinical and Manufacture Department and Drug Safety and Pharmacovigilance Department
Yong-Guo Li
Senior Vice President - Chemical Manufacturing Control
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 5.15 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 9.53 |
LT Debt To Equity (MRQ) | 7.92 |
Return on Investment (TTM) | -32.61 |
Return on Equity (TTM) | -30.40 |
* HUA MEDICINE- DORZAGLIATIN'S PHASE III METFORMIN COMBINATION TRIAL MET PRIMARY EFFICACY AND SAFETY END POINT Source text for Eikon: Further company coverage:
* ANNOUNCES POSITIVE RESULTS OF COMBINATION STUDY OF DORZAGLIATIN WITH EMPAGLIFLOZIN (A SGLT-2 INHIBITOR)
* HUA MEDICINE - BUSINESS OPERATIONS IN CHINA IMPACTED BY OUTBREAK OF NOVEL CORONAVIRUS SINCE LATTER HALF OF JAN
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.